CORESTEMCHEMON Inc. (KOSDAQ:166480)
South Korea · Delayed Price · Currency is KRW
2,700.00
-45.00 (-1.64%)
At close: Mar 12, 2026
Revenue by Segment
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 |
|---|
Cell Therapy Pharmaceutical Sector | 1.56B | 2.12B | 5.49B | 1.57B | 2.21B | | | | | |
Cell Therapy Pharmaceutical Sector Growth | -26.37% | -61.37% | 249.27% | -29.00% | -39.85% | | | | | |
Non-Clinical Trial Agency Division | 27.64B | 32.02B | 40.87B | 29.14B | 24.77B | | | | | |
Non-Clinical Trial Agency Division Growth | -13.67% | -21.66% | 40.25% | 17.66% | 18.42% | | | | | |
| -440.00M | -480.00M | -480.00M | -471.40M | -623.13M | | | | | |
| 28.76B | 33.66B | 45.88B | 30.24B | 26.36B | | | | | |
| -14.54% | -26.64% | 51.71% | 14.73% | 8.54% | | | | | |
Revenue by Geography
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 |
|---|
| 29.18B | 33.93B | 45.88B | 30.24B | 26.36B | | | | | |
| -14.00% | -26.05% | 51.71% | 14.73% | 8.54% | | | | | |
| -440.00M | -480.00M | - | - | - | | | | | |
| 26.57M | - | - | - | - | | | | | |
| - | 210.94M | - | - | - | | | | | |
| 28.76B | 33.66B | 45.88B | 30.24B | 26.36B | | | | | |
| -14.54% | -26.64% | 51.71% | 14.73% | 8.54% | | | | | |
Source: S&P Global Market Intelligence.